Conference Description
The 2019 Conference on Tuberculosis Drug Discovery and Development will feature presentations on breaking science in preclinical and clinical TB drug discovery and development. The talks will serve as primers for in-depth discussions on the unique challenges posed by TB relative to other infectious diseases, and topics will include how drug and target properties relate to efficacy in different models, and how these features might inform clinical trials to realize the goal of treatment shortening. Each session will be designed to address the challenges specific to the topic, and will range from early stage drug discovery to lessons learned in clinical trials.
We invite researchers interested in all aspects of drug discovery and development and welcome participants from academia, industry, government and non-governmental organizations. In particular, we invite trainees and scientists from TB-endemic countries to apply, as their contribution to the struggle against TB is especially important. All participants are asked to submit abstracts of their work for presentation as posters, and some abstracts will be chosen for oral presentations. The conference provides the opportunity to interact with colleagues in an informal and intimate atmosphere and is designed to promote extensive discussion. In the past, the meeting has been oversubscribed – please apply early!
The topics, speakers, and discussion leaders for the conference sessions are displayed below. The conference chair is currently developing their detailed program, which will include the complete meeting schedule, as well as the talk titles for all speakers. The detailed program will be available by March 7, 2019. Please check back for updates.
Keynote Session: Perspectives on TB Drug Development
Discussion Leaders
-
Valerie Mizrahi (Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa)
Speakers
-
Elizabeth Winzeler (University of California, San Diego, USA)
-
Rajesh Gokhale (National Institute of Immunology, India)
Optimizing Drugs for Activity Against the Pathogen
Discussion Leaders
-
Kelly Chibale (University of Cape Town, South Africa)
Speakers
-
Christina Stallings (Washington University School of Medicine, USA)
-
Markus Seeger (University of Zurich, Switzerland)
-
Elizabeth Fullam (University of Warwick, United Kingdom)
-
Kyu Rhee (Weill Cornell Medicine, USA)
-
Shuyi Ma (Seattle Children's Research Institute, USA)
Attributes of an Ideal TB Drug
Discussion Leaders
-
Sabine Ehrt (Weill Cornell Medicine, USA)
Speakers
-
Ben Forbes (King's College London, United Kingdom)
-
Douglas Kell (University of Liverpool, United Kingdom)
-
Veronique Dartois (Rutgers University, USA)
Treatment Shortening Potential of Targets in Cell Wall Biosynthesis
Discussion Leaders
-
David Sherman (Center for Global Infectious Disease Research / University of Washington, USA)
Speakers
-
Hugo Gramajo (Institute of Molecular and Cell Biology of Rosario (IBR-CONICET), Argentina)
-
H. Michael Petrassi (The Scripps Research Institute, USA)
-
Elana Van Brakel (TASK Applied Science, South Africa)
-
Eric Nuermberger (Johns Hopkins University, USA)
Treatment Shortening Potential of Targets in Transcription/Translation
Discussion Leaders
-
Bavesh Kana (University of the Witwatersrand, South Africa)
Speakers
-
Babak Javid (Tsinghua University School of Medicine, China)
-
George Garcia (University of Michigan, USA)
-
Haihong Huang (Institute of Materia Medica, Chinese Academy of Medical Sciences / Peking Union Medical College, China)
-
Brendan Crowley (Merck Research Laboratories, USA)
Treatment Shortening Potential of Non-Traditional Drug Targets
Discussion Leaders
-
Alain Baulard (Institut Pasteur de Lille, France)
Speakers
-
Luiz Pedro Carvalho (The Francis Crick Institute, United Kingdom)
-
Kristin Burns-Huang (Weill Cornell Medicine, USA)
-
Lourdes Encinas (GlaxoSmithKline, Spain)
-
Emily Parker (Victoria University of Wellington, New Zealand)
-
Digby Warner (University of Cape Town, South Africa)
Enrichment of the Pipeline by Natural Products
Discussion Leaders
-
Cynthia Dowd (George Washington University, USA)
Speakers
-
Carole Bewley (National Institutes of Health, USA)
-
Jennifer Herrmann (Helmholtz Institute for Pharmaceutical Research Saarland, Germany)
-
Gerry Wright (McMaster University, Canada)
Host-Dependent and Host-Directed Therapies
Discussion Leaders
-
JoAnne Flynn (University of Pittsburgh School of Medicine, USA)
Speakers
-
David Russell (Cornell University, USA)
-
Chris Sassetti (University of Massachusetts Medical School, USA)
-
Robert Wallis (Aurum Institute, South Africa)
-
Deepak Kaushal (Southwest National Primate Research Center, USA)
Treatment Shortening and Clinical Trials Innovation
Discussion Leaders
-
Gilla Kaplan (University of Cape Town, South Africa)
Speakers
-
Clifton Barry (National Institute of Allergy and Infectious Diseases, NIH, USA)
-
Nick Paton (National University of Singapore, Singapore)
Power Hour
Organizer:
-
Valerie Mizrahi (Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa)
